Targeting the CD70/CD27 pathway has emerged as a potential novel immunotherapeutic strategy, which is already being explored in several early phase clinical trials testing CD70- and CD27-targeting antibodies in various malignancies [17,28,29], but, to date, no standardised method allowing for a comparison of CD70 expression in different tumour types has been published. This evidence concerns the gene CD27 and neoplasm.